BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24707263)

  • 1. Complete Remission of Brain Metastases in Non-Small Cell Lung Cancer Patients Harboring an EGFR Mutation Treated with Tyrosine Kinase Inhibitor without Radiotherapy: A Report of 3 Cases.
    Jung YH; Han CW; Jung YD; Cho YY; Han DJ
    Case Rep Oncol; 2014 Jan; 7(1):149-54. PubMed ID: 24707263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Chen CH; Lee HH; Chuang HY; Hung JY; Huang MY; Chong IW
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
    Jia F; Cheng X; Zeng H; Miao J; Hou M
    J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.
    Sekine A; Satoh H
    Med Oncol; 2017 Jul; 34(7):121. PubMed ID: 28555261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
    Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
    Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
    J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis.
    Wang W; Song Z; Zhang Y
    Arch Med Sci; 2018 Oct; 14(6):1298-1307. PubMed ID: 30393484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.
    Proto C; Imbimbo M; Gallucci R; Brissa A; Signorelli D; Vitali M; Macerelli M; Corrao G; Ganzinelli M; Greco FG; Garassino MC; Lo Russo G
    Transl Lung Cancer Res; 2016 Dec; 5(6):563-578. PubMed ID: 28149752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-Brain Radiotherapy Can Improve the Survival of Patients with Multiple Brain Metastases from Non-Small Cell Lung Cancer Treated by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
    Chen C; Wu Y; Liu BL; Wang HW; Ma JH; Zhou JY
    Cancer Manag Res; 2020; 12():11333-11340. PubMed ID: 33192093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
    Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
    Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.
    McGranahan T; Nagpal S
    Curr Treat Options Oncol; 2017 Apr; 18(4):22. PubMed ID: 28391420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain surgery in combination with tyrosine kinase inhibitor and whole brain radiotherapy for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases.
    Lee HH; Chen CH; Chuang HY; Huang YW; Huang MY
    Sci Rep; 2019 Nov; 9(1):16834. PubMed ID: 31728013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated 
Non-small Cell Lung Cancer and Brain Metastases].
    Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.
    Economopoulou P; Mountzios G
    Transl Lung Cancer Res; 2016 Dec; 5(6):588-598. PubMed ID: 28149754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
    Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.